The benefits of office sinus dilation include:
[i] Stankiewicz J, Truitt T, Atkins J, Winegar B, Cink P, Raviv J, Henderson D, Tami T. Two-year results: transantral balloon dilation of the ethmoid infundibulum. Int Forum Allergy Rhinol. 2012 May; 2(3): 199-206.
[ii] Stankiewicz J, Tami T, Truitt T, Atkins J, Liepert D, Winger B. Transantral, endoscopically guided balloon dilatation of the ostiomeatal complex for chronic rhinosinusitis under local anesthesia. Am J of Rhinology. 2009 May-June; 321-327.
[iii] Gould, J. In-office balloon dilation: Procedure techniques and outcomes using a malleable multi-sinus dilation tool. ENT Journal. Vendome Healthcare Media, 19 Dec 2012.
[iv] Stankiewicz J, Truitt T, Atkins J, Winegar B, Cink P, Raviv J, Henderson D, Tami T. Two-year results: transantral balloon dilation of the ethmoid infundibulum. Int Forum Allergy Rhinol. 2012 May; 2(3): 199-206
Office sinus dilation is a minimally invasive option that can be performed by Dr. Neal right here, in our offices. The goal of office sinus dilation is to reshape anatomy to expand sinus pathways and restore drainage.
The procedure utilizes small balloons placed in key places in the nose and sinus, which are then dilated to expand the sinus pathways. It may be an effective, lasting option for some patients whose symptoms do not resolve with medication.
Kennedy DW, Wright ED, Goldberg AN. Laryngoscope. 2000;110:29–31.
The most common adverse reactions observed in clinical trials were bronchitis, upper respiratory or middle ear infection, headache, light-headedness, asthma and nose bleed. SINUVA is not for people with hypersensitivity to corticosteroids or those with nasal ulcers or trauma. Important Safety Information can be found at https://www.sinuva.com/safety.
Choosing SINUVA Sinus Implants
SINUVA may be appealing to nasal polyp sufferers who would prefer an in-office treatment instead of sinus surgery in an operating room. SINUVA is placed during an office visit and patients are usually able to resume normal activities with little to no recovery days needed.
 SINUVA Prescribing Information, Intersect ENT. December 2017
 Kern RC, Stolovitzky JP, Silvers SL, et al. A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps. Int Forum Allergy Rhinol.2018;8:471–81.
SINUVA was clinically proven to ,
Harrisonburg ENT Associates
Chronic Sinusitis Patients Have A New Weapon - PROPEL
The dissolveable PROPEL Steroid-Releasing Implant is the first in a new category of products offering localized, controlled delivery of steroid directly to the sinus tissue to maintain the openings created in surgery.
Applying principles of coronary drug-eluting stents to sinusitis sufferers, the spring-link implants gradually deliver an advanced steroid with anti-inflammatory properties (mometasone furoate) directly to the sinus lining, then dissolve into the body following endoscopic sinus surgery. The result is improved surgical outcomes, reducing the need for additional surgical procedures and for systematic steroids, which can have serious side effects.
Three rigorous clinical trials4 have demonstrated that the implant is safe and maintains the results of sinus surgery by propping open the sinus cavities and decreasing post-operative scarring and inflammation. Reducing these factors is proven to improve long-term outcomes5 and to reduce the need for repeat surgery and oral steroids, which can have serious side effects. PROPEL is the only product used in sinus surgery to be supported by level 1-A evidence.